Legend Biotech Corp LEGN
- LB2102 — Small Cell Lung Cancer Phase 1
- LB2102 — Large Cell Neuroendocrine Carcinoma Phase 1
DLL3 (3 companies · 4 programs)
Companies with an active program directed at DLL3.
Allogene Therapeutics, Inc. ALLO
- ALLO-213 — Small Cell Lung Cancer
Zymeworks Inc. ZYME
- ZW209 — Small Cell Lung Cancer Preclinical